Analysis of drug properties and uses of talquetamab-tgvs

Talquetamab is an innovative bispecific antibody drug mainly used to treat patients with relapsed or refractory multiple myeloma. It simultaneously recognizes the GPRC5D receptor on the surface of tumor cells and the CD3 molecule on the surface of T cells, guiding T cells directly to the vicinity of tumor cells, thereby enhancing the immune system's specific attack on cancer cells. This precise targeting mechanism significantly improves tumor cell killing efficiency while reducing damage to normal cells. Compared with traditional chemotherapy or monoclonal antibody therapy, Tacistumumab has higher selectivity and potential efficacy, providing a new treatment direction for patients with multiple myeloma. Clinical data shows that the drug can improve tumor burden, delay disease progression, and improve patients' quality of life to a certain extent.

In China, Taquinutumab has been approved for marketing, but it has not yet been included in medical insurance, so patients are under great pressure to purchase the drug out of pocket. Due to the short time on the market, the official domestic selling price is not yet fully clear. In overseas markets, the drug has two main specifications:2mg/ml and 40mg/ml. The price of 2 mg/ml specification is about more than 800 US dollars, while the price of 40 mg/ml specification is about more than 10,000 US dollars. The high price is mainly due to its innovative research and development costs, targeted treatment advantages and clinical research investment.

In actual use, Tacistumumab is usually administered by intravenous infusion or subcutaneous injection, and needs to be assessed before administration, including the patient's immune status, tumor burden, and previous treatment history. Doctors will develop an individualized treatment plan based on the patient's specific conditions and monitor possible side effects during treatment, such as cytokine release syndrome, rash or hematological reactions. Although expensive, Tacistumumab offers new hope and clinical options for patients whose disease has relapsed and for whom traditional treatments have limited efficacy.

Reference materials:https://www.drugs.com